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A PRELIMINARY STUDY OF SUBJECT FACTORS ASSOCIATED WITH  
 
POOR DIFFERENTIATION CAPACITY OF VISCERAL AND  
 
SUBCUTANEOUS ADIPOSE TISSUE IN HUMAN OBESITY  
  
SWATI BHATTACHARYA  
 
ABSTRACT  
        
Background: Fat is stored in adipose tissue. In obesity, differentiation of preadipocytes to 
new adipocytes (fat cells) is required for energy storage. Otherwise fat accumulation in 
non-adipocytes contributes to fatty liver and diabetes.  
Our goal was to assess subject characteristics associated with poor in-vitro differentiation 
capacity of preadipocytes from omental (OM) and abdominal subcutaneous (SC) fat.  
Approach: A convenience sample of, 4 males and 20 females, age 39±2 (range 20–56) 
years, BMI 42 ± 2 (23–63) kg/m2 (i.e. from lean to obese), 7 Caucasian, 8 Hispanic, 1 
other and 8 African Americans) undergoing elective surgery was studied. Fat samples 
collected during surgery were used for histology and preadipocyte isolation. Fat cell 
diameters and their distribution (normal or bimodal) were analyzed from histology. 
Preadipocyte differentiation capacity was measured in vitro. 
Results: In the OM depot, no effect of ethnicity, sex or HbA1c was found. Unexpectedly, 
subjects with preadipocytes with poor differentiation capacity tended to be younger (poor 
differentiation group 36 ± 2 years versus high 43 ± 3 years, p=0.09) and to have lower 
fasting glucose (poor 97 ± 3.65 mg/dl versus high 111 ± 7.08 mg/dl, p=0.06). 
In SC, no differences were noted. Fat cell size was not associated with differentiation 
capacity in either depot. Bimodal distribution, which may show formation of new 
 		 vii  
adipocytes, was seen mostly in Caucasian subjects (5 out of 7) compared to Hispanic (3 
out of 8) and African Americans (2 out of 8).  
Conclusion: It is important to investigate the associations between age/ethnicity and OM 
preadipocyte differentiation/cell distribution in adequately powered cross-sectional 
studies. 
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INTRODUCTION  
1. Definition of Obesity:   
  
Overweight and obesity are defined as excessive fat accumulation, which occurs by 
enlargement of adipose tissue to store excess energy intake. Body Mass Index (BMI) is 
defined as a person’s weight in kilograms divided by the square of his height in meters 
(kg/m2)2.  BMI is a key index of weight for height related to both percentage body fat & 
total body fat and is commonly used to classify underweight, overweight & obesity in 
adults.1 Obesity is a complex, multifactorial metabolic disorder involving genetic, 
environmental (social and cultural), behavioral, psychological and physiological factors. 
These risk factors are commonly associated with cardiovascular disease, Type II diabetes 
mellitus, hypertension, stroke, dyslipidemia, gallbladder disease, hepatic steatosis, sleep 
apnea, endometrial disorder, and cancer.2, 3 Here the term "metabolic" refers to the 
biochemical processes involved in the body's normal functioning. Risk factors are traits, 
conditions, or habits that increase your chance of developing a disease. The 
METABOLIC SYNDROME is a complex disorder unifying dyslipidemia, insulin 
resistance, and hypertension. It is a primary risk factor	for	diabetes	and	cardiovascular	disease. (Goodpaster et al. 2005)  
  
2. Epidemiology of Obesity:   
The most current information from the Center for Disease Control and Prevention (CDC) 
states that more than one-third (34.9%) of adults in US population were obese in 2011– 
2012 (most recent data, Figure 1). More than 78 million adults were obese in that specific 
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period. In 2011–2012, the prevalence of obesity was higher among middle-aged adults 
(39.5%) than among younger (30.3%) or older (35.4%) adults.   
  
Fig.1: Prevalence of 
Obesity Among Adults: 
United States, 2011–2012 
(NCHS Data Brief, No.  
131, October 2013) 
Analyses of trends in 
high weight for 
recumbent length or 
obesity prevalence 
were conducted 
overall and 
separately by age 
across 5 periods 
(2003–2004, 2005–2006, 2007–2008, 2009–2010, and 2011–2012). (Analyses are based 
on measured values of weight and height from the 2011–2012 National Health and 
Nutrition Examination Survey (NHANES) 27  
 
The prevalence of obesity was higher among non-Hispanic black (47.8%), Hispanic  
(42.5%), and non-Hispanic white (32.6%) adults than among non-Hispanic Asian adults 
(10.8%) (Figure 2). The overall prevalence of obesity did not differ between men and 
women in 2011–2012 (Figure 1). Among non-Hispanic black adults, however, 56.6% of 
women were obese compared with 37.1% of men. The most recent national data from 
2011–2012 on obesity prevalence among U.S. adults show that there was no significant 
change since 2009–2010. Given the focus of public health efforts on obesity, surveillance 
of trends in obesity remains important. Overall disparities in obesity prevalence continue 
to exist. Newly available data show a lower prevalence of obesity among non-Hispanic  
Asian adults than among non-Hispanic white, non-Hispanic black, and Hispanic adults.   
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Figure 2. Age-adjusted prevalence of obesity, by sex and race and Hispanic origin, among adults 
aged 20 and over: United States, 2011–2012. SOURCE: CDC/NCHS, National Health and Nutrition 
Examination Survey, 2011–2012.   
Furthermore, obesity prevalence in 2014 varies across states and territories (Figure 3).  
1. No state had a prevalence of obesity less than 20%.  
2. 5 states and the District of Columbia had a prevalence of obesity between 20% 
and <25%.  
3. 23 states, Guam and Puerto Rico had a prevalence of obesity between 25% and 
<30%.  
4. 19 states had a prevalence of obesity between 30% and <35%.  
5. 3 states (Arkansas, Mississippi and West Virginia) had a prevalence of obesity of 
35% or greater.  
6. The Midwest had the highest prevalence of obesity (30.7%), followed by the 
South (30.6%), the Northeast (27.3%), and the West (25.7%).  	 
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Figure 3.  
Prevalence of  
Self-Reported  
Obesity Among  
U.S. Adults by 
State and  
Territory, 
BRFSS,  
2014	 
	 
	 
	 
	  
Health Consequences:  
Obesity increases the risk of a host of obesity related diseases that can afflict 
nearly every organ system in the body.6 It has been directly linked to the world’s leading 
cause of death – cardiovascular disease 7 and to one of the greatest public health threats 
of the 21st century – diabetes1 (Figure 4). According to the National Institutes of Health, 
epidemiological data show a 50% to 100% higher all-cause mortality rate for obese 
patients (BMI of ≥30 kg/m2) than for patients with BMIs of 20 to 25 kg/m2 6  
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Figure 4: Metabolic complications of obesity.  
At a given body mass index (BMI) level, body fat may vary by age, sex, and racial and 
ethnic group (Flegal KM et al.). In particular, at a given BMI, Asian adults may have 
more body fat than white adults. Morbidity and mortality risk may be influenced by 
factors—such as body composition and fat distribution—that are not completely captured 
by BMI (Ogden CL et al.).   
Economic Consequences:  
• Overweight and obesity and their associated health problems have a significant 
economic impact on the U.S. health care system. Medical costs associated with 
overweight and obesity may involve direct and indirect costs. Direct medical costs 
may include preventive, diagnostic, and treatment services related to obesity.   
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• Indirect costs relate to morbidity and mortality costs. Morbidity costs are defined 
as the value of income lost from decreased productivity, restricted activity, 
absenteeism, and bed days. Mortality costs are the value of future income lost by 
premature death.  
• National Estimated Cost of Obesity  
The medical care costs of obesity in the United States are staggering. In 2008 
dollars, these costs totaled about $147 billion.  
  
3. Anatomy of adipose tissue (Fat Depots)     
Adipose is a loose connective tissue that fills up space between organs and tissues and 
provides structural and metabolic support. Adipose tissue / fatty tissue, consists mainly of 
fat cells (adipose cells) and is specialized to synthesize. It contains large globules of fat, 
within a structural network of fibers. Mammals have two different types of adipose: 
white adipose tissue (WAT) and brown adipose tissue (BAT). Here, I will only describe 
white adipose tissue.	White adipose, the most common type, provides insulation, serves 
as an energy store for times of starvation or great exertion, and forms pads between 
organs. When muscles and other tissues need energy, substances known as hormones 
bind to adipose cells and trigger the release of energy-rich fatty acids and glycerol.   
In humans, adipose tissue is found in specific locations, referred as adipose / fat depots.  
Whole body adipose tissue has generally been subdivided in two main components:  
subcutaneous (SC) and internal, visceral adipose tissue (Figure 5).  Subcutaneous adipose 
tissue is usually defined as the layer found between the skin and the aponeuroses and 
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fasciae of the muscles; SC adipose tissue depots store ~ 80–90% of the total body fat, 
mainly in the abdominal & thigh area 7.   
  
Figure 5: Anatomical localization of the main 
abdominal adipose tissue depots.   
Intraperitoneal adipose tissue or so-called 
visceral adipose tissues (VAT) are associated 
with digestive organs, and include the omental 
the mesenteric is composed of two major 
compartments: the omentum (hangs off the 
stomach) and mesenteric (associated with the 
intestine). Intraperitoneal means within or the 
peritoneum. The peritoneum is a thin, transparent 
membrane that lines the walls of the abdominal 
(peritoneal) cavity and contains/encloses the  
abdominal organs. The main white adipose tissues (WATs) are abdominal subcutaneous 
adipose tissue (SAT, and visceral adipose tissue (VAT). VAT surrounds the inner organs 
and can be divided in omental, mesenteric, retroperitoneal: surrounding the kidney, 
gonadal and pericardial. The omental depot stars near the stomach and spleen and can 
expand into the ventral abdomen, while the deeper mesenteric depot is attached in a 
webform to the intestine. The gluteofemoral adipose tissue is the SAT located to the 
lowerbody parts and is measured by hip, thigh, and leg circumference. WAT can also be 
found intramuscularly.  
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Adipose tissues located in and around the abdominal cavity can help deciphering the 
human body fat distribution patterns as well as the pathophysiological association of 
visceral obesity and other metabolic diseases.   
   
4. Type of Obesity: Central versus Peripheral  
Multiple epidemiological studies confirm the detrimental effect of upper-body obesity 
(android-type / apple shape) or central obesity, and the protective effects of lower-body 
obesity (gynoid-type / pear-shape) on diabetes, cardiovascular risk and eventually 
morbidity & mortality.4 Upper body fat distribution is considered as an additional “new” 
independent risk factor for coronary heart disease (CHD), whereas increased lower body 
fat is independently predictive of reduced cardiovascular risk.2 Body fat distribution 
varies with sex, genetic background and aging.5 Women, compared to men, have higher 
percentages of body fat with relatively more deposits of adipose tissue in the hips and 
thighs. This ‘female’ fat distribution, independent of total body fat, confers protection 
against metabolic diseases, such as Type 2 diabetes and atherosclerosis.6			Adipocytes are 
smaller in visceral than subcutaneous (SC) depots in women, while they are similar in  
size in men and extremely obese women.5,12  
Why visceral adiposity is bad  
The dyslipidemic state frequently observed in patients with visceral obesity is a key 
feature of the clustering abnormalities of the metabolic syndrome and has been 
extensively described in the literature. The abnormalities include high levels of 
triglycerides, low levels of high-density lipoprotein (HDL) cholesterol, relatively normal 
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total and low-density lipoprotein (LDL) cholesterol levels, but more LDL particles that 
are smaller and denser than normal. In abdominal obesity, HDL particles are also small in 
size because of the presence of hypertriglyceridemia. Total and LDL cholesterol levels 
are generally within the normal range unless unrelated abnormalities are present. In 
clinical research, hypertriglyceridemia and low HDL cholesterol could be the two major 
detectable blood abnormalities associated with visceral obesity.   
  
Type of fat accumulation: Hypertrophy / Hyperplasia  
 The primary function of the fat cell (adipocytes) is to control energy balance by storing 
triacylglycerol during periods of energy excess and mobilizing it during energy 
deprivation.10 If the adipose organ is unable to accommodate excess energy, the calories 
are stored in the liver and muscles with the development of diabetes.   
Figure 6: The 
inappropriate 
expansion of 
subcutaneous & 
visceral adipose 
tissue (hypertrophic 
obesity) plays a key 
role in metabolic 
abnormalities. 
(Fried et al.)  
 
 
The increased storage of triglycerides in fat cells occurs in two ways: by expanding the 
size of available adipose (fat) cells (hypertrophy), or by recruiting new fat cells by 
increasing their number  
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(hyperplasia).8,9 The size of each fat compartment / depot results from the integration of 
the size and number of lipid-filled adipocytes, which represent the main cellular 
component of adipose tissue. In general, mean adipocyte sizes from all anatomical 
locations and in both sexes increase along with adiposity level, but reach a plateau in 
extremely obese individuals.12 The plateau indirectly suggests that the presence of large 
adipocytes may trigger the generation of new adipocytes to store excess dietary  
fat.   
With regard to visceral adipocyte size and number, lean to moderately obese men tend to 
have larger omental adipocytes than women (Fried SK, Kral JG 1987). In lean to 
moderately obese individuals of both sexes, a strong correlation is observed between 
abdominal subcutaneous adipocyte size and total body fat mass, suggesting that the 
contribution of adipocyte hypertrophy to abdominal adipose tissue expansion may be 
similar in men and women.3 In adult women, expression of genes involved in 
preadipocyte differentiation is relatively higher in subcutaneous than in visceral adipose 
tissue (Drolet R 2008). This finding suggests that in women, expansion of the 
subcutaneous adipose tissue depot relies more heavily on adipocyte hyperplasia than the 
visceral adipose tissue compartment, which may be predominantly hypertrophic	 	 
5. Adipogenesis  
	 
Obesity is also characterized on the basis of adipose tissue cellularity. Adipogenesis, the 
process during which fibroblast-like preadipocytes (precursor fat cells) develop into 
mature adipocytes (fat cells), It is a process by which a less specialized cell becomes a 
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more specialized cell type. In this case, fibroblast like preadipocytes develop into mature 
adipocytes through (commitment & terminal differentiation). This involves cascade of 
transcription factors and cell-cycle proteins regulating gene expression and leading to 
adipocyte development. In order to reach maturity, these cells must go through two vital 
phases: adipocyte determination and adipocyte differentiation.17   
  
Figure 7: Factors affecting preadipocyte commitment Ref: Cawthorn WP et al. J Lipid Res 2012  
  
Figure 7 describes the relationships between SVCs, ASCs, committed preadipocytes, and 
mature adipocytes. SVC is the stromal vascular cells (SVCs) as “primary” preadipocytes, 
which set the stage for extensive characterization of the mechanisms regulating 
adipogenesis and WAT expansion. Determination phase: This stage results in the 
conversion of the Adipose stem cell (ASC) to a committed preadipocyte, which cannot be 
distinguished morphologically from its precursor cell but has lost the potential to 
differentiate into other cell types. Large number of Adipocyte stromal cells (ASC) or 
preadipocytes, are isolated with collagenase digestion of Adipocytes. ASCs are 
multipotent cells (adipogenic, chondrogenic, osteogenic, and myogenic; Cawthorn, 
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Scheller, & MacDougald, 2012b), are capable of expansion in vitro, and can be 
cryopreserved for long periods without significant loss in proliferation and differentiation 
capacity. The differentiated adipocytes display phenotypic characteristics of genuine 
adipocytes, that is, freshly isolated ones.  
Terminal differentiation phase: In this stage, the preadipocyte takes on the 
characteristics of the mature adipocyte. It acquires the machinery that is necessary for 
lipid transport and synthesis, insulin action and the secretion of adipocyte-specific  
proteins.17   
In morbidly obese men and women, SC and OM adipocyte size increases with BMI. In 
women, OM fat cells are smaller than SC cells independent of BMI.16 Severely obese 
patients with healthy metabolic profiles have significantly smaller omental adipocytes 
with increased preadipocyte size compared to a metabolically unhealthy group.13 
According to Anand & Chada, centrally obese people lose the ability to accommodate 
excess energy by differentiating new adipocytes. A study on obese Pima Indians showed 
a strong correlation between fat cell size and difficulty in differentiating new adipocytes 
during the onset of diabetes. Another in vitro study demonstrated that newly 
differentiated adipocytes is greater in lean than in obese subjects.14 The majority of 
studies report that preadipocyte adipogenesis is higher in SC than in OM fat cells. There 
are no other studies found that examined how the ability of primary preadipocytes from 
various fat depots (SC & OM) undergoing in vitro differentiation is associated with 
adipocyte size & visceral obesity.   
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Data from Dr. Fried’s lab show that in most of the obese subjects, visceral fat cells from 
different individuals show wide variations in differentiation capacity. However, it is 
unknown what variables play an important role in triggering these variations. Some 
visceral preadipocytes are unable to differentiate into new mature adipocytes irrespective 
of having good number of OM preadipocytes.   
In very few (10%) cases, omental preadipocytes produce large numbers of mature 
adipocytes compared to the remaining 90% cases where the number of adipocytes 
produced are very small. It is not known what differentiates these two groups of subjects 
(good vs. bad omental differentiators). SC preadipocytes differentiate well in almost all 
subjects. But very little is known about the adipocyte size and its relation with 
differentiation capacity in adult adipocyte cells.   
  
OBJECTIVES  
 
The primary objective of this study is to investigate associations between human 
adipocyte (fat cell) size and the differentiation capacity of preadipocytes (precursor cells) 
in visceral & subcutaneous (SC) fat depots. (DC is measured as total triglyceride content 
in the cell) morbidly obese, obese and lean subgroups will be examined if possible. 
Secondary objective is to assess whether this association is independent of phenotypic 
characteristics & metabolic variables in the subject population (BMI, age, sex, ethnicity,  
Cholesterol, HbA1c & Blood glucose)  
Third objective is to find relation between adipocyte size & metabolic health in the study 
subject population. (The concept of "metabolically healthy obesity" — that is, individuals 
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with a body mass index (BMI) above 30 who do not have metabolic-syndrome factors 
that put them at risk for cardiovascular disease. Up to 35% of obese individuals may be 
metabolically healthy despite their size, the researchers write, but the true prevalence of 
this phenomenon is difficult to assess due to large disparities in defining metabolic 
health).30  
Thesis Question:   
1. In Om depot, is there an association between differentiation capacity and the 
variables listed and the ability of preadipocytes to differentiate (as measured in 
vitro):  
• Cell size  
• Age  
• Sex  
• Race  
• BMI  
• Metabolic characteristics (HbA1c, Blood glucose, Cholesterol)  
2. In SC depot, is there an association between differentiation capacity and:  
• Cell size  
• Age  
• Sex  
• Race  
• BMI  
• Metabolic characteristics (HbA1c, Blood glucose, Cholesterol)  
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HYPOTHESIS:   
1. In the Om depot, the differentiation capacity will be higher in:  
• Subjects with small adipocytes  
• Younger subjects  
• Women  
• Caucasians>Hispanics>AA  
• Obese subjects  
• With normal HbA1c, Cholesterol, FPG  
2. Preadipocytes from subjects with large adipocytes associates with low / poor 
differentiation capacity (DC) in both visceral & SC depots. The above mentioned 
association is independent of other variables (BMI, age, sex, ethnicity, 
Cholesterol, HbA1c & Blood glucose) - which could be confounding factors. 
People having large adipocyte size are more likely to be metabolically unhealthy; 
high HgBA1c, high glucose, independent of BMI, age & sex.  
  
STUDY DESIGN: (Cross-sectional)  
In order to examine the relationship / associations between one or more independent 
variables (age, sex, BMI, adipocyte size, HbA1c, cholesterol) and a dependent variable 
(fat cell Differentiation capacity), as they exist in a convenient population at one 
particular time, a cross-sectional study will be performed. All study measurements will 
be made at a single time-point & no follow-up period involved in this study. This 
primarily involves organizing the subject medical data, calculating mean cell size. Data 
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analysis by finding correlation between differentiation capacity and phenotypic variables 
(cell size, age, sex, BMI) and logistic regression will be done on data collected from a 
population obtained from an investigator initiated clinical study.  
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METHODS   
  
	  Subjects: Sample of adipose tissue were obtained from 24 healthy adults:  
4 males, 20 females, who were lean (n=2, BMI < 25.0 kg/m2), overweight (n=9, BMI: 
25.0 kg/m2 to 30.0 kg/m2) or obese (n=13, BMI > 30.0 kg/m2) who have undergone 
elective surgeries & volunteered for studies of adipose tissue in Fried lab in the Boston 
Medical center. These surgeries included laparoscopic bariatric surgeries: Gastric bypass 
or Sleeve Gastrectomy for weight loss – (abdominal surgeries for severe obesity), kidney 
donors. The participation of the subjects end with the donation of blood and fat sample 
during surgery. Each participant provided written informed consent.  The study was 
approved by the Institutional Review Board of the Boston University School of Medicine 
(Nutritional Regulation of Leptin Production, IRB Number H-28139). Information on the 
height and weight of volunteers, medications, medical conditions and serum levels of 
glucose, HbA1c, blood pressure were obtained from the medical records and recorded in 
lab records with a code number.  
Study subjects were enrolled by the clinical coordinators, PI on the basis of the 
elective surgery they were undergoing at BMC and therefore women are no more 
vulnerable than the other participants. Pregnant women are not enrolled. No children (< 
18 years) were enrolled for this study. Potential subjects were given the time to think 
about participation in the study and were encouraged to ask questions of the investigators 
or their own doctors. If potential volunteers were contacted on the day of their surgery, 
and were willing to discuss participation in our study, we proceed to describe the purpose 
and procedures involved in the study, and risks, and ask them to sign an informed 
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consent. Subjects provided written informed consent before their inclusion in the study 
and copies of the signed consent from were placed in: 1) the patient's research chart, 2) 
the investigator's locked cabinet.   
Inclusion criteria:   
Participants were required to be healthy, or type 2 diabetic, 18 to 80 years of age, having 
BMI > 19 kg/m2, scheduled for elective surgery, free of major organ disease, physical 
impairment limiting normal activity, current cancer, unstable cardiac disease, other 
unstable system disorders that are not being treated, untreated Endocrine disorders, such 
as hypo- or hyperthyroidism, pituitary disorders, etc., except Type 2 Diabetes, polycystic 
ovarian syndrome and Cushing’s syndrome.   
Ethical Statement: The sample size mentioned in BMC IRB application is 243, which is 
for a far more complex & big study & it’s still ongoing. My study is a part of that 
approved study for which I have selected 24 subjects having data available with 
differentiation capacity. To understand how fat cell function changes in obesity, and in 
particular how the fat cells regulates the production of leptin, we will study these 
processes in samples of human adipose tissue obtained from patients undergoing elective 
surgery.  We sample fat from different places in the body (called depots), because we 
know that they act differently.  Once we obtain a fat sample, all tests will be conducted in 
test tubes.     
The study (IRB # H-28139) is approved by the ethics committee of our institution & all 
24 subjects (selected from a large pool of participants) gave written informed consent 
before the beginning of the study. Subjects were included in the study only once they met 
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the inclusion / exclusion criteria. There is a check off in Informed consent form so the 
subject can agree to be re-contacted for future studies. There is also a check off to 
determine whether subjects will agree to bank their tissue & DNA for genetic testing.   
Adipose tissue sampling, adipocyte isolation, and cell size measurement   	 
We obtained blood and subcutaneous -omental adipose tissue samples from the 24 
subjects. Four of the 24 patients are diagnosed with pre-diabetic borderline to type 2 
diabetes (DM2). Approximately 1–3 gms of omental adipose tissue, or 1 gms of 
abdominal subcutaneous adipose tissue, was obtained at the time of bariatric & other 
types of surgery. Subcutaneous adipose tissue samples were collected at site of the 
surgical incision (lower abdomen) while omental samples were removed from the distal 
part of the greater omentum. A piece of this tissue was immediately fixed in Z-fix, prior 
to paraffin mounting and preparation of H&E slides. The remaining tissue was placed in 
M-199 transported to the lab, and processed within 1 hour and used for adipocyte 
isolation.   
Blood Sampling: Blood samples were taken on the day of the surgery in the overnight 
fasting state. Serum was separated with centrifugation for 15 min at 2500 rpm and 4°C 
and stored at -80°C for future analyses.  
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Fat cell size and number calculation:  
The fixed tissue was sent to laboratory of Tufts University Department of Histology core 
for slicing, and H&E staining. Cells were sized after digital photography using imaging 
software (Image J, NIH). Two hundred fifty cell size as adipocyte area (µm2) and 
diameters per depot (µm) were calculated by Photoshop & Image J software.    
Average volume of adipocytes were measured by the weighted average volume method.   
  
The demographic and metabolic characteristics (Age, sex, BMI, Cholesterol level,  
HbA1c) of the participating subjects were recorded from the hospital medical chart via 
BMC logician access. These variables will be studied and compared to find correlation 
with fat cell differentiation capacity.   
Statistical Analysis: Data are presented as mean and their standard errors, unless 
otherwise indicated. A paired t-test (two-tailed distribution) was carried out to compare 
the mean adipocyte size in Subcutaneous (SC) & visceral (OM) depots in the selected 
subject population.  A non-paired t-test was carried out to compare age, BMI, HbA1c, 
FPG, cholesterol between good & poor differentiation groups. Differences among race 
categories were analyzed by 1-way ANOVA, followed by Tukey’s post-hoc test. A P 
value of <0.05 was considered as statistically significant. Statistical analyses were 
performed with the Graph pad Prism 5 (Graph Pad, a Jolla, CA) software.   
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RESULTS  
1. Subject Characteristics  
Samples from twenty-four subjects were available for the preliminary analyses planned.  
Subject characteristics are shown in Table 1.   83% were females (n=20) and 17% (n=4) 
males. Their age varied from 20–56 years with overall mean age of 39 ± 1.96 years. 
Their mean BMI was 42 ± 2.10 kg/m2 (range 23– 63 kg/m2).  
The study included 8 (F7 M1) African Americans, 7 (F7) Caucasians, and 8 (F6, M2) 
Hispanics (Table 1). The participants underwent laparoscopic surgery: 17 subjects had 
gastric bypass, 5 subjects had sleeve gastrectomy, and 2 had donor nephrectomy and their 
characteristics are described in Table 1.  
 Variables  Overall Men Women Caucasians AA Hispanics 
p value 
between 
races 
   (n= 24) (n= 4) (n= 20) (n=7) (n=8) (n=8)    
Age (y)  39 ± 1.96 (20–56) 
30 ± 3.63 
(20–37) 
41 ± 2.04 
(20–56) 
45.3 ± 3.0 
(35–56) 
39.1 ± 2.8 
(24–48) 
36.3 ± 3.3 
(20–48) 0.1457  
BMI 
(kg/m2) 
42 ± 2.10 
(23–63) 
55 ± 2.72 
(50–63) 
39 ± 1.99 
(23–54) 
40 ± 0.78 
(38–44) 
45 ± 3.35 
(25–55) 
40 ± 3.51 
(23–63) 0.4809  
Cholesterol 
(mg/dl)  
198 ± 7.72 
(157–280) 
179.3 ± 6.0 
(162–190) 
203.1 ± 9.4 
(157–280) 
197.3 ± 14.93 
(172–280) 
207.3 ± 14.57 
(157–257) 
193.5 ± 7.3 
(183–215) 0.7957  
HbA1c 
(%)  
6 ± 0.098 
(5.1–6.8) 
6 ± 0.25 
(5.5–6.6) 
6 ± 0.10 
(5.1–6.8) 
6.1 ± 0.14 
(5.7–6.8) 
5.9 ± 0.22 
(5.1–6.6) 
5.9  ± 0.14 
(5.7–6.3) 0.6576  
Glucose 
(mg/dl)  
102 ± 3.76 
(77–139) 
106 ± 12.7 
(77–139) 
101 ± 3.79 
(84–131) 
106 ± 7.24 
(84–131) 
101 ± 4.99 
(88–124) 
99 ± 9.1 
(77–139) 0.7844  	 
Table 1: Subjects characteristics with metabolic variables  
BMI: Body mass Index (weight in kilograms divided by the square of the height in 
meters)   AA: African Americans    Data shown as Mean ± SEM  
  
The women in this sample were older (p = 0.0386) and less obese (lower BMI) 
(p=0.0023) as compared to men.  
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2. Differences in cell volume between OM and SC  
In the total population, SC adipocytes were larger than omental adipocytes: 309.1 
± 29.44 vs 480.7 ± 35.73 pl,	p = 0.006, as previously reported in the literature.  
Figure 8: Mean of Fat cell volume vs. SC-OM depot.  
Fat cell volume vs. depot 
 
Depot 
	 
Photos of histology sections from one representative subject are shown in (Figure 9).	The 
sections are stained with H&E stains. The outlines of the cells were traced and perimeters 
were measured from which the cell diameter was calculated.  
                                           
Figure 9: Cell images showing larger adipocytes in SC (right) compared to OM (left) 
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In some subjects, a bimodal distribution was found: i.e. the volumes of the cells did not 
follow a normal distribution, but two populations of small and large adipocytes were 
found (Figure 10).  
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Fig 10: Histograms of cells volumes (pl) in Om and SC from two different subjects. (X 
axis: %, Y axis: bins)  
  
The subjects (48-OM, 143-OM, 218-OM-SC, 220-SC and 74 SC) that showed bimodal 
distribution were all women, Caucasian, age 36 and 56 years old, with BMI range of 38– 
40. Subject 14-OM is the only AA male with BMI 55.  
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Then, OM and SC cell volume were compared in subgroups (paired t test- it is a within 
person paired comparison).  
  
a. Men and women  
In men (n=4), OM cell volume was 388.8 ± 24.72 pl, which was smaller (not statistically 
significant) than SC cell volume 458.5 ± 60.69 pl (N=4, p= 0.3281).  
 In women (n=20), OM cell volume was 293.2 ± 34.05 pl, which was smaller than SC 
cell volume 485.1 ± 41.62 (N=20, p= 0.0010***).  
b. AA and Hispanics  
In AA subjects, OM cell volume was 301.4 ± 57.04 pl, which was smaller than SC cell 
volume 484.8 ± 42.41 pl, (n= 8, p= 0.0218*).  
In Hispanic subjects, OM cell volume was 255.3 ± 42.90 pl, which was tended to be 
smaller than SC cell volume 356.5 ± 28.62 pl, (n=8, p=	0.0698).  
c. Correlations between OM-SC cell volume and age, BMI, cholesterol,  
Blood glucose level   
d. The results are shown below (Table 2). There was a close to significant 
correlation between fat cell volume and BMI in the OM depot (r = 0.3775, p =  
0.0689), but not in the SC depot (Figure 11).  
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Table 2: Correlations between FCV (OM-SC) & metabolic parameters   
    
Variables  OM cell volume  SC cell volume  
   r  p  r  p  
Age (Y) 0.0449  
0.8348  
(ns)  0.1481  
0.4898  
(ns)  
BMI (kg/m2) 0.3775  
0.0689  
(ns)  0.1551  
0.4693  
(ns)  
Cholesterol 
(mg/dl) -0.0619  
0.8073  
(ns)  -0.3244  
0.189  
(ns)  
Glucose 
(mg/dl) 
  
0.208  
  
0.3655  
(ns)  
  
-0.1628  
  
0.4809  
(ns)  
  
	 
Figure 11: Correlation of FCV (OM-SC) with BMI   
  
Cell size Vol. (OM) –BMI Cell size (SC)-BMI 
 
	 BMI (kg/m2) BMI 
	 
  
3. Comparison between the Poor & Good Differentiation groups in OM depot 
Preadipocytes from the OM depot differentiated poorly in 14 subjects and average in 10 
subjects. The preadipocyte differentiation was done by another group of people and the 
data were available in the lab. Their characteristics are shown in Table 3.  
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Table 3: describes the relationship between subject characteristics & differentiation 
capacity of OM.  
   Mean Differentiation ± SEM (OM)   
   Medium  Poor  p value  
Characteristics  (n=10)  (n=14)     
Age (y)  43 ± 2.87 (31–56)  36 ± 2.49 (20–48)  0.095  
BMI (kg/m2)  40 ± 3.45  43 ± 2.7  0.5  
Sex  M= 1 (10%) F=9 (90%)  M= 3 (21.4%) F=11 (78.5%)     
Race  
C=5 (50%),   
AA=2 (20%),   
H=3 (30%)  
C=2 (14.3%),   
AA= 6 (42.9%), 
H=5 (35.7%)  
  
Cholesterol (mg/dl)  205 ± 12.29  192 ± 10  0.4071  
HbA1c (%) 6  ± 0.08  6 ± 0.16  0.98  
Blood Glucose 
(mg/dl) 111 ± 7.08  97 ± 3.65  0.057  
Hx of Diabetes  Y=2  Y=2     
BMI: Body mass Index, AA: African American, C: Caucasian, H: Hispanic  
Data shown as Mean ± SEM  
Subjects with medium differentiation capacity did not differ from those with poor 
differentiation capacity in age, BMI and metabolic variables. These differences may not 
be statistically significant due to small sample size but some are close to being 
statistically significant: subjects with OM preadipocytes with medium differentiation 
tended to be older (43 ± 2.87 years) compared to subjects with preadipocytes poor 
differentiation capacity (36 ± 2.49 years) (p value 0.095). Also subjects with poor DC 
tended have lower blood glucose level (97 ± 3.65 mg/dl) compared to subjects with 
medium DC having higher blood glucose level (111 ± 7.08 mg/dl) with a p value of  
0.057.   
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Next the cell volume in OM adipose tissue was calculated from histology sections. No 
difference was noted between Poor and Medium differentiators (Table 4).  
Table 4: Comparison between the Poor & Good Differentiation groups in OM depot  
  
   
   
Mean Differentiator ± SEM (OM)  
Medium  Poor  p value  
Characteristics  (n=10)  (n=14)     
Cell size-vol (pl)  333.9 ± 47.7   291.4 ± 38.0   0.4892  
 
  
4. Comparison between the Poor & Good Differentiation groups in SC depot  
Table 5 describes the relationship between subject characteristics & differentiation 
capacity of SC.  
   Mean Differentiation ± SEM (SC)  
 
   High  Med  p value  
Characteristics  (n=16)  (n=8)     
Age (y)  41.44 ± 2.3  34.75 ± 3.2  0.1105  
BMI (kg/m2)  40.75 ±2.68  44.88 ± 3.36  0.3679  
Sex  
M=1 (6.25%) F=15 
(93.7%)  
M=3 (37.5%) F=5 
(62.5%)     
Race  
AA=3 (18.7%),   
C=7 (43.75%),   
H=6 (37.5%)  
AA=5 (62.5%),  
H=2 (25%)    
Cholesterol (mg/dl)  197.9 ± 9.6  197.7 ± 13.9  0.9906  
HbA1c (%) 6 ± 0.1   5.9 ± 0.2  0.7346  
Blood Glucose (mg/dl) 103.2 ± 5.3  101 ± 5.19   0.789  
Hx of Diabetes  y=3  Y=1     
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Subjects with high differentiation capacity did not differ from those with medium 
differentiation capacity in age, BMI and other metabolic variables. No statistical 
significant associations were found & this could be due to small sample size.   
The cell volume in SC adipose tissue was calculated from histology sections. No 
significant difference was noted between high and medium differentiators (Table 6).  
  
Table 6: Comparison between the Poor & Good Differentiation groups in SC depot  
  
   
   
Mean Differentiator ± SEM (SC)  
High  Med  p value  
Characteristics  (n=16)  (n=8)     
Cell size-vol (pl)  502.4 ± 49.37  437.3 ± 41.67  0.4023  
  
 
  
 30	
DISCUSSION  
  
It was hypothesized that preadipocytes from subjects with large adipocytes associates 
with low / poor differentiation capacity (DC) in both visceral & SC depots. We have 
examined whether the differentiation of preadipocytes is influenced by any metabolic 
factors. The findings from our lab (Dept. of Medicine, Section of Endocrinology, 
Diabetes and Nutrition) does not support the hypothesis as we didn’t find any significant 
association of adipocyte size and difference in differentiation capacity in SC & OM 
depots. Our data indicate that, under a defined differentiation program, abdominal SC and 
OM preadipocytes from lean to obese men and women differentiate similarly in primary 
culture. No significant differences were found in fat cell size and clinical characteristics 
with good & poor differentiator in SC-OM depot.  Due to the lack of associations found, 
no further statistical tests were performed to check whether any confounding factors were 
involved in the study.	It’s also found that people with poor DC in OM depot have lower 
blood glucose level compared to the SC depot. But the opposite is not true.   
A slight trend of cell size increase with BMI is seen by using both the methods that’s 
been used for cell size calculation. This result supports the established fact of 
hypertrophy that occurs in both fat compartments as SC & OM adipocyte sizes increases 
with BMI in men & women.11  
The lack of statistical significance is likely due to the small number of cases; however 
this finding should not be completely dismissed because it has been observed in other 
studies.  This is a possible trend that warrants further investigation in future studies.  
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Depot-specific adipogenic differences, specifically those between SC and OM 
preadipocytes, have been investigated previously in other studies, but only to a limited 
extent. Our finding of SC depot having higher DC (qualitative) compared to OM depot is 
in agreement with a report based on 14 women (obese and non-obese) showed that 
abdominal SC preadipocytes have a 4.5-fold greater differentiation capacity than those of 
the intra-abdominal OM region.  
An additional observation was a trend showing correlation between BMI and omentum 
cell size but not of subcutaneous cells. A dependence of adipocyte size on age & BMI                                                      
has been shown previously.31 However, a novel finding may be that this relation might 
not be true for the omental region. This observation could be important as studies in 
humans suggest that aging & BMI is associated with a preferential growth of the omental 
adipose tissue in both men and women. This underlines the role of regional differences in 
adipose tissue growth.  
There were no major gender differences with regard to preadipocyte differentiation and 
proliferation in this study. These correlations were not found in the study group, probably 
because this group was too small to perform any valid linear regression analysis.  
Limitations: There are several limitations to this project.  The first limitation is the 
sample size of the study population. This could have potentially affected the precision 
and accuracy of the data reported as some of the results are quite close to statistical 
significant. A larger sample would have been preferable because it may have resulted in a 
more stable estimate of the population parameters. As a result, the conclusions of this 
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study may be based off of a varied data set and caution should be used when interpreting 
these findings.  
Secondly, the DC is data is based on the qualitative value. Overall, the induction of 
differentiation was satisfactory, as indicated qualitatively by the morphological extent of 
differentiation. Quantitative data on DC, which were unavailable during the course of this 
thesis, would have been more helpful to interpret the results in more accurate way.   
Thirdly, the ratio of male & female population is not balanced.   
In fourth, no measures of body fat and fat distribution were assessed. Adipocytes 
numbers in each depot can be calculated to compare with the in vitro results.   Finally, 
the results of this study can only be generalized to populations similar to those treated 
at Boston Medical Center.  While that was the original intent of the study, it also 
becomes a limitation if an attempt is made to compare the data to other heterogeneous 
populations, which should also be studied before one is able to make solid statements 
surrounding the prevalence of obese patients in general population.   
  
Future Directions: Further studies powered for race, age and sex are needed to address 
the proposed question. Since most of the study population was severely obese, it’s 
important to study non-obese male & female. A subject population with more men need 
to be studied to understand if there is a sex difference and a race difference (match for 
BMI, AGE).  
In conclusion, the results of this study indicate that there may exist regional differences in 
adipose tissue growth with special reference to proliferation capacity, whereas no 
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substantial difference in differentiation capacity between subcutaneous and omental 
preadipocytes was observed. A clinically interesting aspect was that adipocyte cell size 
increased with BMI only in the omental but not the subcutaneous depot, which could 
contribute to the preferential expansion of the SC adipose tissue depots with BMI.	  
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